

**Virginia's Department of Medical Assistance Services  
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, Virginia 23219*

**Thursday, October 18, 2012 - 10:00 a.m.**

**Welcome and Comments from DMAS' Director**

**Cynthia B. Jones**

**Comments from the Secretary of Health and Human Resources**

**The Honorable William Hazel, M.D.**

**Call to Order**

**Randy Axelrod, M.D., Chairman**

**Drug Utilization Review (DUR) Board Update**

**Avtar Dhillon, M.D., DMAS DUR Board**

**Magellan Health Update**

**Debbie Moody, R.Ph., Clinical Manager**

**Approval of Minutes From April 19, 2012 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

• **Old Business**

- Pradaxa<sup>®</sup> - fax form and criteria up-date

• **PDL Phase II – New Drug Review**

- Erythropoiesis Stimulating Proteins
  - Omontys<sup>®</sup>
- Herpes Topical
  - LidoVir<sup>™</sup>
- Non-ergot Dopamine Receptor Agonist
  - Neupro<sup>®</sup>
  - ropinirole er
- Platelet Aggregation Inhibitors
  - clopidogrel
- Short-Acting Narcotics
  - Primlev<sup>™</sup>
- Topical Agents for Psoriasis
  - Sorilux<sup>™</sup>

• **PDL Phase I – Annual Review**

- **Antivirals**
  - Hepatitis C

- **Cardiac Medications**

- Angiotensin Modulators
  - Angiotensin-Converting Enzyme (includes combination products)
  - Angiotensin II Receptor Antagonists (includes combination products)
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine & non-dihydropyridine agents)
- Direct Renin Inhibitors
- Lipotropics
  - HMG CoA Reductase Inhibitors-Statins (includes combinations with niacin, CAI agent, CCBs)
  - Other (includes Fibric Acid derivatives, Omega 3 fatty acid, Niacin, Bile Acid Sequestrants and CAI agent)

- **Cardiac Medications (continued)**
  - Pulmonary Hypertension Agents (PDE-5 Inhibitors; Endothelin-1 agents and Prostacyclin analogues)
- **Central Nervous System**
  - Sedative Hypnotics and Other Hypnotics
- **Endocrine & Metabolic Agents**
  - Growth Hormones
  - Progestins for Cachexia
- **Gastrointestinal**
  - Histamine-2 Receptor Antagonists
  - Proton Pump Inhibitors
  - Ulcerative Colitis (oral and rectal)
- **Genitourinary**
  - Bladder Relaxants
  - BPH Agents (includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitor for BPH treatment)
  - Phosphate Binders
- **Immunologic Agents**
  - Topical Immunomodulators
- **Respiratory**
  - Antihistamines – Second Generation (LSAs)
  - Beta Adrenergics – (includes short acting, long acting, nebulized and combinations)
  - COPD: Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors
  - Corticosteroids (includes nebulized solutions, metered dose inhalers and combinations)
  - Intranasal Antihistamines and Corticosteroids
  - Self-Injectable Epinephrine

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee, DMAS & PS Staff  
Pursuant to 42 USC §1396r-8**

**PDL Recommendations and Vote**

**P&T Committee Members**

**Criteria Discussion of Phase II New Drugs\***

**P&T Committee Members**

**Criteria Discussion of PDL Phase I Drug Classes\***

**P&T Committee Members**

**Next Meeting – April, 2013**

**Randy Axelrod, M.D., Chairman**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2011 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2010 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Friday, September 21, 2012.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by 5 p.m. EST on **September 21, 2012.**

DRAFT